Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's Centralized Patient Affairs Office Aims For No Disruption

Executive Summary

New office will develop agency-wide patient engagement policy and serve as entry point for patient groups new to FDA, but will not interfere with existing relationships between advocates and the drugs and biologics centers, FDA Commissioner Gottlieb says.

You may also be interested in...



US FDA Is Dedicating A 'Patient Affairs' Staff Without A Formal Reorg

The agency's principle deputy commissioner says it's creating a patient affairs staff, but will not undergo a reorganization.

US FDA's Patient Affairs Office Is An Office … In Spirit

Rachel Sherman says agency is creating patient affairs staff, but will not undergo reorganization to create an official office.

Gottlieb Promotes 'Team' Work For Product Reviews

US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.

Related Content

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel